Multiple Sclerosis News Today Forums Forums Trials and Research Mapi Pharma, Mylan Partner to Develop Once-monthly Glatiramer Formulation

  • Mapi Pharma, Mylan Partner to Develop Once-monthly Glatiramer Formulation

    Posted by MS News Today Moderator on April 13, 2018 at 6:41 am

    Mylan and Mapi Pharma will jointly develop and commercialize Glatiramer Acetate (GA) Depot, an investigative, long-lasting formulation of the commonly used multiple sclerosis (MS) therapy Copaxone (marketed by Teva Phatmaceutical).

    Under the terms of the partnership, Mylan will acquire global marketing rights for the therapy.

    The companies are in the process of preparing an investigational new drug application to be submitted to the U.S. Food and Drug Administration, as well as to other global health authorities. Also, they will initiate a pivotal Phase 3 clinical trial to support a future marketing application for GA Depot.

    “As one of Israel’s leading biotech companies, we are pleased and excited to have partnered and collaborated with Mylan in bringing this very important new product to the millions of MS patients around the globe,” Ehud Marom, CEO and chairman of Mapi Pharma, said in a press release.

    “GA Depot is expected to significantly improve the mode of treatment for patients with MS by reducing the number of injections, easing the treatment burden, and increasing patient compliance,” Marom added.

    Read more about this here: “Mapi Pharma, Mylan Partner to Develop Once-monthly Glatiramer Formulation

    Have you ever used Copaxone to treat MS? Share your experience and your thoughts below.

    MS News Today Moderator replied 6 years, 1 month ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.